|Support type:||Scholarships in Brazil - Master|
|Effective date (Start):||August 01, 2012|
|Effective date (End):||July 31, 2014|
|Field of knowledge:||Health Sciences - Medicine - Pathological Anatomy and Clinical Pathology|
|Principal researcher:||Luiz Felipe Domingues Passero|
|Grantee:||Bruno Luiz Soares Campos|
|Home Institution:||Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil|
The antigens released by parasites are interesting targets for the development of vaccine candidates, once they firstly interact with the innate immune system establishing an intrinsic physiological interaction with the host cell. Therefore, these antigens have been the target for the development of vaccines against murine and canine experimental leishmaniasis. Yet, with the recent publication of the Leishmania donovani secretome was possible to develop well-defined vaccine candidates against this tropical disease; however, a limiting factor is the yield of this type of antigen for further purification. Thus, DNA vaccines are good alternatives to overcome the problem of protein purification, since the target proteins are expressed in vivo. In the present project the immunogenic and protective effects of two different DNA vaccines produced with iron-superoxide dismutase and serine peptidase from L. (Leishmania) amazonensis, which will be carried by pVAX1 bacterial plasmid, already licensed for human use will be assayed. BALB/c mice will be immunized with DNA vaccine three times at regular intervals of 15 days intramuscularly. After 30 days of the last vaccination, six animals will be sacrificed and immunological tests will be conducted to analyze the immunogenicity of vaccines. For analysis of protection, BALB/c will be immunized and after 30 days will be challenged subcutaneously in the footpad with L. (L.) amazonensis promastigotes. Immunological, functional and histopathological experiments will be conducted to examine the efficacy of these vaccines. Furthermore, analysis of the function of CD4+ and CD8+T lymphocytes will be analyzed through passive transference. Re-infection can be performed. This project aims to contribute to the development of vaccine candidates against American Tegumentar Leishmaniasis.